NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
|
|
|
IUPAC Traditional name
|
(2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
|
|
|
Synonyms
|
(2S)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
|
(S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
|
OstarineNOT FOR SALE-PATENTED
|
MK-2866
|
Ostarine(MK-2866)
|
GTx-024
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
11.946099
|
H Acceptors
|
5
|
H Donor
|
2
|
LogD (pH = 5.5)
|
3.2725205
|
LogD (pH = 7.4)
|
3.2725086
|
Log P
|
3.2725208
|
Molar Refractivity
|
95.0509 cm3
|
Polarizability
|
34.619236 Å3
|
Polar Surface Area
|
106.14 Å2
|
Rotatable Bonds
|
6
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Selleck Chemicals
TRC
Selleck Chemicals -
S1174
|
Protocol
|
Kinase Assay
[1]
|
In vitro competitive radioligand binding assay |
The AR binding affinity of Ostarine is determined using an in vitro competitive radioligand binding assay with [3H]mibolerone (MIB). Briefly, increasing concentrations (0.01-5000 nM) of Ostarine are incubated with rat cytosol, a saturating concentration of [3H]-MIB (1 nM), and 1000 nM triamcinolone acetonide to prevent interaction of MIB with progesterone receptors at 4 °C for 18 hours. At the end of incubation, free and bound [3H]-MIB are separated using the hydroxyapatite method. IC50 value is determined by computer-fitting the data for each ligand by nonlinear regression analysis. |
Animal Study
[1]
|
Animal Models |
Immature castrated male Sprague-Dawley rats |
Formulation |
Dissolved in DMSO, and diluted in saline |
Doses |
1 mg/day |
Administration |
Subcutaneous injection |
|
Toronto Research Chemicals -
O703500
|
Nonsteroidal selective androgen receptor modulator (SARM) used in the treatment of osteoporosis and muscle wasting in animal models. A potential compound for the treatment of hypoactive sexual desire disorder. |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Kim J, et al. J Pharmacol Exp Ther, 2005, 315(1), 230-239.
- • Duke CB, et al. J Med Chem, 2011, 54(11), 3973-3976.
- • Jones, A. et al.: J. Pharmacol. Exp. Therap., 224, 439 (2010)
- • Thevis, M. et al.: Drug Test. Anal., 2, 589 (2010)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent